DrugPatentWatch Database Preview
Alemtuzumab - Biologic Drug Details
Email this page to a colleague
» See Plans and PricingSummary for alemtuzumab
| Tradenames: | 2 |
| Patents: | 378 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for alemtuzumab |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for alemtuzumab |
Recent Clinical Trials for alemtuzumab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Northwestern University | Phase 2 |
| M.D. Anderson Cancer Center | Phase 1 |
Recent Litigation for alemtuzumab
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Celgene Corporation v. Aurobindo Pharma Limited | 2018-07-06 |
| CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD. | 2018-06-28 |
| AMGEN INC v. SANDOZ INC. | 2018-06-26 |
See all alemtuzumab litigation
PTAB Litigation
| Petitioner | Date |
|---|---|
| GEMoaB Monoclonals GmbH | 2019-12-20 |
| 2018-01-08 | |
| 2017-11-17 |
Pharmacology for alemtuzumab
| Mechanism of Action | CD52-directed Antibody Interactions |
Company Disclosures: US Patents for alemtuzumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | Burroughs Wellcome Co. (Research Triangle Park, NC) | 2013-08-13 | RX | Orphan | company |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | Burroughs Wellcome Co. (Research Triangle Park, NC) | 2013-08-13 | RX | Orphan | company |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | Burroughs Wellcome Co. (Research Triangle Park, NC) | 2014-08-05 | RX | Orphan | company |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | British Technology Group Limited (London, GB) | 2015-12-08 | RX | Orphan | company |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-12-28 | RX | Orphan | company |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | BTG International Limited (London, GB) | 2020-05-27 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for alemtuzumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) | 2028-04-10 | RX | Orphan | search |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | University of Georgia Research Foundation, Inc. (Athens, GA) | 2039-02-26 | RX | Orphan | search |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | AbbVie Stemcentrx LLC (North Chicago, IL) | 2033-02-08 | RX | Orphan | search |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | University of the Sciences of Philadelphia (Philadelphia, PA) | 2034-11-21 | RX | Orphan | search |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | INNATE PHARMA S.A. (Marseilles, FR) | 2023-07-24 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for alemtuzumab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Singapore | 187426 | Start Trial |
| European Patent Office | 2111869 | Start Trial |
| Canada | 2866452 | Start Trial |
| Canada | 2300663 | Start Trial |
| South Korea | 20120125379 | Start Trial |
| Taiwan | 201823455 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for alemtuzumab
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2016 00026 | Denmark | Start Trial | PRODUCT NAME: ALEMTUZUMAB; REG. NO/DATE: EU/1/13/869 20130916 |
| 2016019 | Lithuania | Start Trial | PRODUCT NAME: ALEMTUZUMABAS; REGISTRATION NO/DATE: EU/1/13/869 20130912 |
| /2016 | Austria | Start Trial | PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 (MITTEILUNG) 20130916 |
| 2016000055697 | Italy | Start Trial | PRODUCT NAME: ALEMTUZUMAB(LEMTRADA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/869, 20130916 |
| 199051 | Germany | Start Trial | PRODUCT NAME: MABCAMPATH-ALEMTUZUMAB IN ALLEN SEINEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/01/193/001 20010706 |
| 0967 | Netherlands | Start Trial | PRODUCT NAME: TISAGENLECLEUCEL; REGISTRATION NO/DATE: EU/1/18/1297 20180827 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
